A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: Adjunctive pharmacotherapy during and after inpatient treatment

被引:65
作者
Kabel, DI [1 ]
Petty, F [1 ]
机构
[1] UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DALLAS, TX 75235 USA
关键词
alcoholism; fluoxetine; selective serotonin reuptake inhibitors;
D O I
10.1111/j.1530-0277.1996.tb01686.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Twenty-eight male patients with severe alcohol dependence (mean pretreatment consumption of 18.6 standard drinks per day) completed a placebo-controlled, double-blind clinical trial of fluoxetine (60 mg/day). They were assigned to medication group in the second of 4 weeks an a voluntary inpatient chemical dependency ward and continued medication during a 12-week follow-up phase. Fluoxetine did not reduce clinically significant relapse rates: only 8 of 15 (53%) of fluoxetine subjects remained sober at 12 weeks, compared with 9 of 13 (69%) of the placebo group (Fisher's exact test, p = 0.46). Subjects with comorbid cocaine dependence relapsed more than twice as often (3 of 4, 75%) as those with alcohol dependence alone (8 of 24, 33%), although this trend did not reach statistical significance because of the small number of dually dependent subjects (Mann Whitney U test = 68, p = 0.13). Supportive living arrangements after hospital discharge did reduce relapse rates: 8 of 9 subjects (89%) discharged to a Veterans Affairs domiciliary were sober at 12 weeks, compared with 9 of 19 (47%) subjects discharged back to the community (Mann-Whitney U test = 125, p = 0.02). Fluoxetine-treated subjects who remained sober at 12 weeks reported a significant decrease in mean subjective alcohol craving scores from 2.9 to 0.7 on a 10-point scale (t = 2,828, p = 0.02). In summary, fluoxetine did not reduce clinical relapse rates in this sample of male severe alcoholics without other axis I disorders who completed 4 weeks of inpatient alcoholism treatment.
引用
收藏
页码:780 / 784
页数:5
相关论文
共 32 条
[1]   EFFECT OF CITALOPRAM ON ALCOHOL INTAKE IN HEAVY DRINKERS [J].
BALLDIN, J ;
BERGGREN, U ;
ENGEL, J ;
ERIKSSON, M ;
HARD, E ;
SODERPALM, B .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1994, 18 (05) :1133-1136
[2]   THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE [J].
BERGSTROM, RF ;
BEASLEY, CM ;
LEVY, NB ;
BLUMENFIELD, M ;
LEMBERGER, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (04) :261-266
[3]  
CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573
[4]  
CORNELIUS JR, 1995, PSYCHOPHARMACOL BULL, V31, P297
[5]  
CORNELIUS JR, 1993, PSYCHOPHARMACOL BULL, V29, P195
[6]   DIAGNOSTIC CRITERIA FOR USE IN PSYCHIATRIC RESEARCH [J].
FEIGHNER, JP ;
WOODRUFF, RA ;
WINOKUR, G ;
MUNOZ, R ;
ROBINS, E ;
GUZE, SB .
ARCHIVES OF GENERAL PSYCHIATRY, 1972, 26 (01) :57-&
[7]   EFFECTS OF FLUOXETINE AND CA-ACETYL-HOMOTAURINATE ON ALCOHOL INTAKE IN FAMILIAL AND NONFAMILIAL ALCOHOLIC PATIENTS [J].
GERRA, G ;
CACCAVARI, R ;
DELSIGNORE, R ;
BOCCHI, R ;
FERTONANI, G ;
PASSERI, M .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1992, 52 (02) :291-295
[8]   EFFECT OF FLUOXETINE ON ALCOHOL-CONSUMPTION IN MALE ALCOHOLICS [J].
GORELICK, DA ;
PAREDES, A .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1992, 16 (02) :261-265
[9]   FLUOXETINE IS INEFFECTIVE FOR TREATMENT OF COCAINE DEPENDENCE OR CONCURRENT OPIATE AND COCAINE DEPENDENCE - 2 PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS [J].
GRABOWSKI, J ;
RHOADES, H ;
ELK, R ;
SCHMITZ, J ;
DAVIS, C ;
CRESON, D ;
KIRBY, K .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (03) :163-174
[10]  
KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391